Welcome!
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.
We are working to edit the videos and post them on our site but meanwhile -- please feel free to view the unedited versions now in YouTube (to view the full playlist, click the three lines in the upper left corner. )
To move to the next video in the playlist click SHIFT-N):
Discussions from the patient forum included:
NGS: Current Status, Barriers and Emerging Targets
Joshua Bauml, MD
Charu Aggarwal, MD
Hossein Borghaei, DO, MS
Helena Yu, MD
H. Jack West, MD
Charu Aggarwal, MD
Melina Marmarelis, MD
Joshua Sabari, MD
Joshua Bauml, MD
Joshua Sabari, MD
Helena Yu, MD
H. Jack West, MD
Christine Cambareri, PharmD, BCPS, BCOP
Jill Feldman, Patient Advocate
Ivy Elkins, Patient Advocate
View faculty bios here
For questions and comments, please join the conversation in our community forums!

Please feel free to offer comments and raise questions in our
discussion forums.
Hi app.92, Welcome to Grace. I'm sorry this is late getting to you. And more sorry your mum is going through this. It's possible this isn't a pancoast tumor even though...
A Brief Tornado. I love the analogy Dr. Antonoff gave us to describe her presentation. I felt it earlier too and am looking forward to going back for deeper dive.
Dr. Singhi's reprise on appropriate treatment, "Right patient, right time, right team".
While Dr. Ryckman described radiation oncology as "the perfect blend of nerd skills and empathy".
I hope any...
My understanding of ADCs is very basic. I plan to study Dr. Rous’ discussion to broaden that understanding.
Here's the webinar on YouTube. It begins with the agenda. Note the link is a playlist, which will be populated with shorts from the webinar on specific topics
An antibody–drug conjugate (ADC) works a bit like a Trojan horse. It has three main components:
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.